Formulated Palmitoylethanolamide Supplementation Improves Parameters of Cognitive Function and BDNF Levels in Young, Healthy Adults: A Randomised Cross-Over Trial
Background: Palmitoylethanolamide (PEA) is an endocannabinoid-like lipid mediator which is naturally produced in the body and found in certain foods. The aim of this study was to assess the effect of a bioavailable formulated form of PEA (Levagen+<sup>®</sup>) on serum BDNF levels and pa...
Main Authors: | Nadia Kim, Brenda Parolin, Derek Renshaw, Sanjoy K. Deb, Mohammed Gulrez Zariwala |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-02-01
|
Series: | Nutrients |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6643/16/4/489 |
Similar Items
-
A randomised controlled trial assessing the potential of palmitoylethanolamide (PEA) to act as an adjuvant to resistance training in healthy adults: a study protocol
by: Zoya Huschtscha, et al.
Published: (2023-03-01) -
ALIAmides Update: Palmitoylethanolamide and Its Formulations on Management of Peripheral Neuropathic Pain
by: Ramona D’Amico, et al.
Published: (2020-07-01) -
The Efficacy of Palmitoylethanolamide (Levagen+) on the Incidence and Symptoms of Upper Respiratory Tract Infection—A Double Blind, Randomised, Placebo-Controlled Trial
by: Amanda Rao, et al.
Published: (2023-10-01) -
The Protective Effects of Pre- and Post-Administration of Micronized Palmitoylethanolamide Formulation on Postoperative Pain in Rats
by: Rosalba Siracusa, et al.
Published: (2020-10-01) -
Therapeutic Use of Palmitoylethanolamide as an Anti-Inflammatory and Immunomodulator
by: Maria Clara Inácio de Sá, et al.
Published: (2023-12-01)